Lipocine Inc. (NASDAQ:LPCN) Short Interest Update

Lipocine Inc. (NASDAQ:LPCN) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 157,602 shares, a growth of 41.9% from the December 15th total of 111,083 shares. Based on an average daily trading volume, of 234,076 shares, the short-interest ratio is currently 0.7 days. Currently, 3.0% of the shares of the company are sold short. Currently, 3.0% of the shares of the company are sold short. Based on an average daily trading volume, of 234,076 shares, the short-interest ratio is currently 0.7 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Citadel Advisors LLC acquired a new position in Lipocine Inc. (NASDAQ:LPCN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,247 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned 0.26% of Lipocine as of its most recent SEC filing. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LPCN has been the subject of a number of research reports. HC Wainwright decreased their target price on Lipocine from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Lipocine has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Lipocine Trading Down 1.2%

Lipocine stock traded down $0.13 during midday trading on Friday, reaching $11.13. 244,760 shares of the stock traded hands, compared to its average volume of 206,857. Lipocine has a fifty-two week low of $2.52 and a fifty-two week high of $12.37. The firm has a market cap of $61.79 million, a price-to-earnings ratio of -10.91 and a beta of 0.92. The firm has a fifty day moving average price of $4.97 and a two-hundred day moving average price of $3.69.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). Lipocine had a negative net margin of 126.67% and a negative return on equity of 30.65%. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.24 million.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.